Czechia· CZ-0290520
RHAPSIDO
A remibrutinib product containing remibrutinib, registered in Czechia by Novartis Europharm Limited, Dublin. The same ATC class is registered in 9 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Remibrutinib is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AA60 (remibrutinib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 6 of them publish a price we can compare per daily dose
Remibrutinib · ATC L04AA60
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Switzerlandprice
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- REMIBRUTINIB
- Manufacturer
- Novartis Europharm Limited, Dublin
- Country
- Czechia (CZ)
- ATC code
- L04AA60
- ATC class
- Remibrutinib
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Remibrutinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainRHAPSIDO 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandRhapsidoNovartis Europharm Limited
- IrelandRhapsido 25 mg film-coated tabletsNovartis Europharm Limited
- IcelandRhapsidoNovartis Europharm Limited*
- NetherlandsRhapsido 25 mg filmomhulde tablettenNovartis Europharm Limited
- PolandRhapsidoNovartis Europharm Limited
- BelgiumRhapsido 25 mgNovartis Europharm
- SwedenRhapsido 25 mg Filmdragerad tablettNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rhapsido
- Liechtenstein · Rhapsido
- Norway · Rhapsido
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/52e1d2e4-0493-427c-aa3e-dc0f88a79112 GET /v1/drugs/52e1d2e4-0493-427c-aa3e-dc0f88a79112?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "25MG",
"pack_size": "60",
"substance": "REMIBRUTINIB",
"cz_kod_sukl": "0290520",
"product_type": "CH",
"substance_codes": "22352",
"registration_state": "R",
"registration_number": "EU/1/26/2024/002"
}See everything about remibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.